If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 6 of 6
A Multicenter, Randomized, Double-Blind, Parallel-Group Study To Assess The Efficacy And Safety Of Oral Etrasimod as Induction And Maintenance Therapy For Moderately To Severely Active Crohns Disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)
Protocol No
GI-ARENA-CULTIVATE-CD
Categories
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Crohn's Disease: The OPTIMIZE Trial
Proactive Infliximab Optimization Using a PK Dashboard Versus SOC in Patients With Crohn's Disease: The OPTIMIZE Trial
Protocol No
GI-BIDMC-OPTIMIZE
Categories
Assessment of Cardiovascular Risk in Inflammatory Bowel Disease Patients
Cardiovascular Risk in IBD
Protocol No
GI-IIT-SINH-CV-IN-IBD
Categories
Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)
Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD)
Protocol No
GI-YARUR-SPARC
Categories
Pregnancy in Inflammatory Bowel Disease And Neonatal Outcomes: Long-Term Outcomes of In-Utero Biologic and Thiopurine Exposure (PIANO)
Pregnancy in Inflammatory Bowel Disease And Neonatal Outcomes (PIANO)
Protocol No
GI-UCSF-PIANO
Categories
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis
Oral NX-13 in Moderate to Severe Ulcerative Colitis
Protocol No
GI-LANDOS-NX-13-201
Categories